Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 20, 2019
Pharmacy Choice - Pharmaceutical News - Sawai Pharmaceutical Co., Ltd. - MHLW Approves New Indication for ARGATROBAN Injection - March 20, 2019

Pharmacy News Article

 1/10/19 - Sawai Pharmaceutical Co., Ltd. - MHLW Approves New Indication for ARGATROBAN Injection

Osaka - Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of partial change applications by the Ministry of Health, Labour and Welfare (MHLW) for ARGATROBAN Injection 10 mg [SAWAI].

This approval expands the indication of ARGATROBAN Injection 10 mg [SAWAI] to include the same uses as their brand equivalents.

Brand products: Novastan HI Injection 10 mg / 2 mL and Slonnon HI Injection 10 mg / 2 mL

'Indications and Usage' and 'Dosage and Administration' after approvals are described below (New approval is underlined);

Indications and Usage

Improvement of neurological symptoms (motor paralysis) and activities of daily living (walking, standing, maintaining a sitting position, diet) associated with the following diseases: Acute cerebral thrombosis within 48 hours after the onset of symptoms (excluding lacunar type)

Improvement of ulcers of the extremities, pain at rest, and cold sensation associated with chronic arterial occlusion (Buerger's disease and arteriosclerosis obliterans)

Prevention of blood coagulation in extracorporeal circuit in the following patients (during haemodialysis)

Patients with congenital antithrombin III deficiency

Patients with decreased antithrombin III

(When antithrombin III decreased to less than 70% within the normal range, and heparin sodium or heparin calcium did not improve clotting (residual blood) in the extracorporeal circulation.)

Patients with heparin-induced thrombocytopenia (HIT) type II

Prevention of blood coagulation undergoing percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (HIT) type II (including cases at risk of developing)

Prophylaxis of thrombosis in patients with heparin-induced thrombocytopenia (HIT) type II

Dosage and Administration

Improvement of neurologic symptoms (motor paralysis) and activities of daily living (walking, standing, maintaining a sitting position, diet) associated with the following diseases: Acute cerebral thrombosis within 48 hours after the onset of symptoms (excluding lacunar type)

In general, for adults, 6 ampules (60 mg as argatroban hydrate) diluted with fluid are administered by continuous intravenous injection once daily over a period of 24 hours for the first 2 days. One ampule (10 mg as argatroban hydrate) diluted with an appropriate volume of fluid is administered by intravenous injection twice a day for the next 5 days, in the morning and evening, over a period of 3 hours. The dosage may be adjusted according to the patient's age and symptoms.

Improvement of ulcers of the extremities, pain at rest, and cold sensation in patients with chronic arterial occlusion (Buerger's disease and arteriosclerosis obliterans) In general, for adults, 1 ampule (10 mg as argatroban hydrate) diluted with an appropriate volume of fluid is administered by intravenous injection twice a day over a few hours. The dosage may be adjusted according to the patient's age and symptoms

Prevention of blood coagulation in extracorporeal circuit in the following patients (during haemodialysis)

Patients with congenital antithrombin III deficiency

Patients with decreased antithrombin III

Patients with heparin-induced thrombocytopenia (HIT) type II

In general, for adults, 1 ampule (10 mg as argatroban hydrate) is administered into the circuit at the beginning of extracorporeal circulation, followed by 2.5 ampules (25 mg as argatroban hydrate) administered every hour after extracorporeal circuit start. The dosage may be adjusted for individual patients based on prolongation of coagulation time, blood clot in the circuit (residual blood), dialysis efficiency, and hemostasis at the end of dialysis. The standard dosage is 0.5 to 4 ampules (5 to 40 mg as argatroban hydrate) per hour

Prevention of blood coagulation undergoing percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (HIT) type II (including cases at risk of developing) In general, for adults, 0.1 mg/kg as argatroban hydrate diluted with an appropriate volume of fluid is administered (can be administrated undiluted) intravenously over a period of 3 to 5 minutes, and 6 g/kg/minute as argatroban hydrate is administered by continuous intravenous infusion for 4 hours after surgery. If continuous anticoagulation is required, the dosage should be reduced to 0.7 g/kg/minute. This dosage of continuous intravenous infusion is just an approximatestandard; the dosage may be adjusted appropriately under coagulation monitoring.

Prophylaxis of thrombosis in patients with heparin-induced thrombocytopenia (HIT) type II In general, for adults, 0.7 g/kg/minute as argatroban hydrate diluted with an appropriate volume of fluid is administered (can be administrated undiluted) by intravenous injection followed continuous infusion. Start at a low dosage in patients with hepatic function disorder or at risk of bleeding. In addition, the dosage may be adjusted based on the activated partial thromboplastin time (aPTT), and determined for individual patients.

About Sawai

Founded in 1929, Sawai Pharmaceutical Co., Ltd. has grown into one of the leading generics companies in Japan. Guided by its corporate philosophy, 'Always Putting Patients First,' Sawai markets more than 700 high-quality generic products and reliably delivers them to patients throughout Japan. In 2017, Sawai acquired US-based Upsher-Smith Laboratories, LLC marking its first step in overseas expansion to become a globally recognized generic pharmaceutical company.

The product announced in this press release is not approved by the Food & Drug Administration for sale and distribution in the United States.

Contact:

Tel: 1-800-525-8747



(C) 2019 Electronic News Publishing

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Mar 20: Opioid Pharmacology: A Review of Pharmacodynamics and Pharmacokinetics
Last Chance
Mar 21: HIV Medications: Newer Drugs, Newer Guidelines
Last Chance
Mar 22: NSAIDs, Acetaminophen and Adjuvants in Pain Management
Mar 24: A Look Inside the Top 200 Drugs
Mar 25: Medication Use During Pregnancy & Lactation
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415